| Steroid hormone biosynthesis |
33 |
CYP3A4, HSD3B2, CYP3A5, HSD3B1, CYP1B1, HSD17B2, HSD17B1, CYP11B1, COMT, UGT1A7, AKR1C3, UGT1A6, UGT1A9, UGT1A3, UGT1A4, UGT2A1, HSD17B6, HSD17B3, SRD5A1, UGT2A3, SULT1E1, HSD17B7, AKR1C1, CYP19A1, HSD17B8, CYP1A1, UGT1A1, UGT1A10, UGT2B17, CYP17A1, UGT2B15, AKR1D1, UGT2B7 |
4.86E-49 |
| Metabolism of xenobiotics by cytochrome P450 |
26 |
GSTA1, CYP3A4, CYP3A5, CYP1B1, SULT2A1, CYP1A1, EPHX1, GSTT1, UGT1A1, DHDH, GSTM1, UGT1A7, UGT1A10, GSTM2, UGT1A6, UGT1A9, UGT2B17, GSTM3, UGT1A3, UGT1A4, UGT2A1, UGT2A3, UGT2B15, UGT2B7, AKR1C1, GSTP1 |
3.29E-31 |
| Chemical carcinogenesis |
24 |
GSTA1, CYP3A4, CYP3A5, CYP1B1, SULT2A1, CYP1A1, EPHX1, GSTT1, UGT1A1, UGT1A7, GSTM1, UGT1A10, UGT1A6, GSTM2, UGT1A9, UGT2B17, GSTM3, UGT1A3, UGT1A4, UGT2A1, UGT2A3, UGT2B15, UGT2B7, GSTP1 |
8.08E-27 |
| Drug metabolism-cytochrome P450 |
20 |
GSTA1, CYP3A4, CYP3A5, GSTT1, UGT1A1, UGT1A7, GSTM1, UGT1A10, UGT1A6, GSTM2, UGT1A9, UGT2B17, GSTM3, UGT1A3, UGT1A4, UGT2A1, UGT2A3, UGT2B15, GSTP1, UGT2B7 |
6.4E-22 |
| Retinol metabolism |
16 |
CYP3A4, CYP3A5, CYP1A1, UGT1A1, UGT1A7, UGT1A6, UGT1A10, UGT1A9, UGT2B17, UGT1A3, UGT1A4, UGT2A1, HSD17B6, UGT2A3, UGT2B15, UGT2B7 |
3.57E-16 |
| Pentose and glucuronate interconversions |
13 |
UGT1A7, UGT1A10, UGT1A6, UGT1A9, UGT2B17, UGT1A3, UGT1A4, UGT2A1, UGT2A3, UGT2B15, UGT1A1, DHDH, UGT2B7 |
1.02E-15 |
| Ascorbate and aldarate metabolism |
12 |
UGT1A7, UGT1A10, UGT1A6, UGT1A9, UGT2B17, UGT1A3, UGT1A4, UGT2A1, UGT2A3, UGT2B15, UGT1A1, UGT2B7 |
3.81E-15 |
| Ovarian steroidogenesis |
14 |
AKR1C3, HSD3B2, IGF1R, CYP17A1, HSD3B1, CYP1B1, CYP1A1, HSD17B2, INS, HSD17B1, IGF1, GNAS, HSD17B7, CYP19A1 |
6.86E-15 |
| Drug metabolism-other enzymes |
13 |
CYP3A4, UGT1A7, UGT1A10, UGT1A6, UGT1A9, UGT2B17, UGT1A3, UGT1A4, UGT2A1, UGT2A3, UGT2B15, UGT1A1, UGT2B7 |
1.01E-13 |
| Porphyrin and chlorophyl metabolism |
12 |
UGT1A7, UGT1A10, UGT1A6, UGT1A9, UGT2B17, UGT1A3, UGT1A4, UGT2A1, UGT2A3, UGT2B15, UGT1A1, UGT2B7 |
1.10E-12 |
| Prolactin signaling pathway |
12 |
AKT1, MAPK1, FOS, CYP17A1, CCND1, INS, ESR1, PIK3CA, MAPK11, ESR2, PRL, SRC |
4.99E-10 |
| Thyroid hormone signaling pathway |
12 |
AKT1, MAPK1, NCOA1, CCND1, NCOA2, NCOA3, ESR1, PIK3CA, NCOR1, MYC, SRC, MED1 |
9.09E-08 |
| Estrogen signaling pathway |
10 |
AKT1, MAPK1, FOS, JUN, ESR1, PIK3CA, NOS3, GNAS, ESR2, SRC |
2.26E-06 |
| Metabolic pathways |
32 |
CYP3A4, HSD3B2, CYP3A5, HSD3B1, HSD17B2, HSD17B1, CYP11B1, COMT, AKR1C3, UGT1A7, UGT1A6, UGT1A9, POLE4, UGT1A3, UGT1A4, UGT2A1, HSD17B6, HSD17B3, NOS3, UGT2A3, HPGDS, HSD17B7, CYP19A1, HSD17B8, CYP1A1, UGT1A1, UGT1A10, UGT2B17, CYP17A1, UGT2B15, AKR1D1, UGT2B7 |
1.18E-05 |
| Prostate cancer |
8 |
AKT1, MAPK1, IGF1R, AR, CCND1, INS, PIK3CA, IGF1 |
7.70E-05 |
